REG - IRIS SPV PLC - SUBSTITUTION OF IRIS II SPV DAC AND CLARIS IV LTD

MaximusAnnouncement

30/06/2020 15:15

RNS Number : 5698R
  
IRIS SPV PLC
  
30 June 2020
  
 





Company name


SOCIETE GENERALE




Headline


SUBSTITUTION OF IRIS II SPV DESIGNATED ACTIVITY COMPANY AND CLARIS IV LIMITED WITH IRIS SPV PLC ON

30 JUNE 2020




RNS Number 5698R

Iris II SPV Designated Activity Company

Claris IV Limited

Iris SPV plc 
Company Announcement

 
Iris II SPV Designated Activity Company
(formerly Iris II SPV Limited)
Fourth Floor, 76 Lower Baggot Street
Dublin 2
Ireland
 
Claris IV Limited
IFC 5
St Helier
Jersey
JE1 1ST
 
(each an "Issuer" and together the "Issuers")
 
Iris SPV plc
Fourth Floor
76 Lower Baggot Street
Dublin 2
Ireland


30 June 2020 
RE: SUBSTITUTION OF ISSUER
Substitution of the Issuers in connection with notes issued under the EUR 20,000,000,000 Secured Transaction Programme of Claris Limited, Claris 2 Limited, Claris III Limited, Claris IV Limited, Iris SPV plc and Iris II SPV Designated Activity Company (the "Programme") with Iris SPV plc
Iris II SPV Designated Activity Company wishes to announce that, pursuant to the written consent of the noteholders on 29 June 2020, it entered into:
(1)  a deed of amendment dated 29 June 2020 in relation to the Series 100/2014 Notes (as defined below) under the Programme between Iris SPV plc, HSBC Corporate Trustee Company (UK) Limited, HSBC Bank plc and HSBC France, Dublin Branch, pursuant to which, Iris SPV plc assumed all rights, obligations and liabilities of Iris II SPV Designated Activity Company in respect of the Series 100/2014 Notes and the Transaction Documents insofar as the same relate to the Series 100/2014 Notes and agreed to acquire the Mortgaged Property as defined in the Principal Trust Deed and Iris II SPV Designated Activity Company was released and discharged from all its obligations and liabilities in respect of the Series 100/2014 Notes, the Transaction Documents and the Iris II Custody Agreement insofar as the same relates to the Series 100/2014 Notes;
 
(2)  a deed of amendment dated 29 June 2020 in relation to the Series 101/2014 Notes (as defined below) under the Programme between Iris SPV plc, HSBC Corporate Trustee Company (UK) Limited, HSBC Bank plc and HSBC France, Dublin Branch, pursuant to which, Iris SPV plc assumed all rights, obligations and liabilities of Iris II SPV Designated Activity Company in respect of the Series 101/2014 Notes and the Transaction Documents insofar as the same relate to the Series 101/2014 Notes and agreed to acquire the Mortgaged Property as defined in the Principal Trust Deed and Iris II SPV Designated Activity Company was released and discharged from all its obligations and liabilities in respect of the Series 101/2014 Notes, the Transaction Documents and the Iris II Custody Agreement insofar as the same relates to the Series 101/2014 Notes;
 
(3)  a deed of amendment dated 29 June 2020 in relation to the Series 102/2014 Notes (as defined below) under the Programme between Iris SPV plc, HSBC Corporate Trustee Company (UK) Limited, HSBC Bank plc and HSBC France, Dublin Branch, pursuant to which, Iris SPV plc assumed all rights, obligations and liabilities of Iris II SPV Designated Activity Company in respect of the Series 102/2014 Notes and the Transaction Documents insofar as the same relate to the Series 102/2014 Notes and agreed to acquire the Mortgaged Property as defined in the Principal Trust Deed and Iris II SPV Designated Activity Company was released and discharged from all its obligations and liabilities in respect of the Series 102/2014 Notes, the Transaction Documents and the Iris II Custody Agreement insofar as the same relates to the Series 102/2014 Notes;
 
(4)  a deed of amendment dated 29 June 2020 in relation to the Series 103/2016 Notes (as defined below) under the Programme between Iris SPV plc, HSBC Corporate Trustee Company (UK) Limited, HSBC Bank plc and HSBC France, Dublin Branch, pursuant to which, Iris SPV plc assumed all rights, obligations and liabilities of Iris II SPV Designated Activity Company in respect of the Series 103/2016 Notes and the Transaction Documents insofar as the same relate to the Series 103/2016 Notes and agreed to acquire the Mortgaged Property as defined in the Principal Trust Deed and Iris II SPV Designated Activity Company was released and discharged from all its obligations and liabilities in respect of the Series 103/2016 Notes, the Transaction Documents and the Iris II Custody Agreement insofar as the same relates to the Series 103/2016 Notes;
 
(5)  a deed of amendment dated 29 June 2020 in relation to the Series 104/2016 Notes (as defined below) under the Programme between Iris SPV plc, HSBC Corporate Trustee Company (UK) Limited, HSBC Bank plc and HSBC France, Dublin Branch, pursuant to which, Iris SPV plc assumed all rights, obligations and liabilities of Iris II SPV Designated Activity Company in respect of the Series 104/2016 Notes and the Transaction Documents insofar as the same relate to the Series 104/2016 Notes and agreed to acquire the Mortgaged Property as defined in the Principal Trust Deed and Iris II SPV Designated Activity Company was released and discharged from all its obligations and liabilities in respect of the Series 104/2016 Notes, the Transaction Documents and the Iris II Custody Agreement insofar as the same relates to the Series 104/2016 Notes; and
 
(6)  a deed of amendment dated 29 June 2020 in relation to the Series 105/2018 Notes (as defined below) under the Programme between Iris SPV plc, HSBC Corporate Trustee Company (UK) Limited, HSBC Bank plc and HSBC France, Dublin Branch, pursuant to which, Iris SPV plc assumed all rights, obligations and liabilities of the Iris II SPV Designated Activity Company in respect of the Series 105/2018 Notes and the Transaction Documents insofar as the same relate to the Series 105/2018 Notes and agreed to acquire the Mortgaged Property as defined in the Principal Trust Deed and Iris II SPV Designated Activity Company was released and discharged from all its obligations and liabilities in respect of the Series 105/2018 Notes, the Transaction Documents and the Iris II Custody Agreement insofar as the same relates to the Series 105/2018 Notes.
 
Claris IV Limited wishes to announce that, pursuant to the written consent of the noteholders on 29 June 2020, it entered into:
(1)     a deed of amendment dated 29 June 2020 in relation to the Series 106/2016 Notes (as defined below) under the Programme between Iris SPV plc, HSBC Corporate Trustee Company (UK) Limited, HSBC Bank plc and HSBC France, Dublin Branch, pursuant to which, Iris SPV plc assumed all rights, obligations and liabilities of Claris IV Limited in respect of the Series 106/2016 Notes and the Transaction Documents insofar as the same relate to the Series 106/2016 Notes and agreed to acquire the Mortgaged Property as defined in the Principal Trust Deed and Claris IV Limited was released and discharged from all its obligations and liabilities in respect of the Series 106/2016 Notes, the Transaction Documents and the Claris IV Custody Agreement insofar as the same relates to the Series 106/2016 Notes.




ISIN


Description 
 




XS1079436256


Series 100/2014 (formerly Series 22/2014) Tranche 1 EUR 50,000,000 OAT 2035 Collateral Fixed Income Structured Interest Notes due 2035 issued pursuant to the Programme (the "Series 100/2014 Notes")




XS1119793831


Series 101/2014 (formerly Series 25/2014) EUR 125,000,000 Multi-Collateral Fixed Income Structured Interest Notes due 2035 issued pursuant to the Programme (the "Series 101/2014 Notes") 




XS1118204061


Series 102/2014 (formerly Series 26/2014) EUR 200,000,000 OAT 2035 Collateral Fixed Income Structured Interest Notes due 2035 issued pursuant to the Programme (the "Series 102/2014 Notes")




XS1514033874


Series 103/2016 (formerly Series 30/2016) EUR 223,100,000 Structured Index Linked Notes due 2027 issued pursuant to the Programme (the "Series 103/2016 Notes")




XS1514033957


Series 104/2016 (formerly Series 31/2016) EUR 223,200,000 Structured Index Linked Notes due 2027 issued pursuant to the Programme (the "Series 104/2016 Notes")




XS1929548433


Series 105/2018 (formerly Series 32/2018) EUR 100,000,000 Structured Index Linked Notes due 2031 issued pursuant to the Programme (the "Series 105/2018 Notes")




XS1415010898


Series 106/2016 (formerly Series 49/2016) Tranche 1 EUR 80,000,000 OAT 2029 Credit Linked Notes due 2029 issued pursuant to the Programme (the "Series 106/2016 Notes")




                                              
There has been no significant change in the financial or trading position of Iris II SPV Designated Activity Company and no material adverse change in the financial position or prospects of Iris II SPV Designated Activity Company since the date of the most recently published accounts for the financial year ended 30 June 2019. There has been no significant change in the financial or trading position of Claris IV Limited and no material adverse change in the financial position or prospects of Claris IV Limited since the date of the most recently published accounts for the financial year ended 30 June 2019.
There are no governmental, legal or arbitration proceedings (including any such proceedings which are pending or threatened of which either Issuer is aware) which may have, or have had since the incorporation of Iris II SPV Designated Activity Company on 28 May 2007 and the incorporation of Claris IV Limited on 7 September 2006, a significant effect on its financial position or its profitability. 
 
For further information please contact:

 
Sanne Capital Markets Ireland Limited

Attn: The Board of Directors

Fax: +353 1 906 2201

Email: SanneAdminIre@sannegroup.com
 
 
 
This announcement has been issued through the Companies Announcement Service of Euronext Dublin.
 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
ISEURAORRRUNOAR